Table 2.
Rate of late-stent thrombosis: sirolimus-eluting, paclitaxel-eluting, drug-eluting, and bare metal stents
| Author | Trial | Patients (N) | Length of follow-up | Thrombosis rates by stent type (SES/PES/DES/BMS) | |
|---|---|---|---|---|---|
| Kereiakes et al 2006 | Pooled analysis | SES: 337 | 1080 days | SES: 0% | |
| BMS: 0.4% | BMS: 238 | ||||
| Moreno et al 2005 | Meta-analysis | DES: 2602 | — | DES: 0.58% | SES: 0.11% |
| BMS: 2428 | BMS: 0.54% | PES: 0.29% | |||
| Park et al 2006 | Single center, all comers | SES: 1545 | 18 months | DES: 0.8% | |
| PES: 366 | |||||
| Schampaert et al 2004 | Pooled analysis | SES: 758 | 2 years | SES: 0.4% | |
| BMS: 752 | BMS: 0.5% | ||||
| Bavry et al 2005 | Meta-analysis | SES: 1515 | 13.5 months | SES: 0.07% | |
| BMS: 1448 | BMS: 0.48% | ||||
| Weisz et al 2006 | SIRIUS trial | SES: 533 | 361–720 days | SES: 0.9% | |
| BMS: 525 | BMS: 1.5% | ||||
| Urban et al 2006 | e-CYPHER registry | SES: 15157 | 12 months | SES: 0.19% | |
| lakovou 2005 | Prospective observational cohort study | SES: 1062 | 9 months | SES: 0.8% | |
| PES: 1167 | PES: 1.7% | ||||
Abbreviations: BMS, bare metal stents; DES, drug-eluting stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents.